Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

NDAQ:CPRX - Post by User

Catalyst Pharmaceuticals Inc

Bullboard Posts

Post by BlueCitizenon Sep 03, 2009 9:22am

484 Views

Post# 16274053

Any idea why ?

Would welcome any input on this company and specifically to their reason behind the decision below ,

Thanks,

CORAL GABLES, Fla., Sept 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) has received approval from The NASDAQ Stock Market to transfer the listing of its common stock from The NASDAQ Global Market(R) to The NASDAQ Capital Market(R). The transfer will be effective at the opening of the market on September 3, 2009. Catalyst will continue to trade under the symbol "CPRX" with no impact on the ability of investors to trade the stock.

The NASDAQ Capital Market(R) is a continuous trading market that operates in the same manner as The NASDAQ Global Market(R). The NASDAQ Capital Market(R) includes the securities of approximately 450 companies. All companies listed on The NASDAQ Capital Market(R) must meet certain financial requirements and adhere to NASDAQ's corporate governance standards.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload